Literature DB >> 14698276

Inflammation: the link between insulin resistance, obesity and diabetes.

Paresh Dandona1, Ahmad Aljada, Arindam Bandyopadhyay.   

Abstract

Recent data have revealed that the plasma concentration of inflammatory mediators, such as tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), is increased in the insulin resistant states of obesity and type 2 diabetes, raising questions about the mechanisms underlying inflammation in these two conditions. It is also intriguing that an increase in inflammatory mediators or indices predicts the future development of obesity and diabetes. Two mechanisms might be involved in the pathogenesis of inflammation. Firstly, glucose and macronutrient intake causes oxidative stress and inflammatory changes. Chronic overnutrition (obesity) might thus be a proinflammatory state with oxidative stress. Secondly, the increased concentrations of TNF-alpha and IL-6, associated with obesity and type 2 diabetes, might interfere with insulin action by suppressing insulin signal transduction. This might interfere with the anti-inflammatory effect of insulin, which in turn might promote inflammation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14698276     DOI: 10.1016/j.it.2003.10.013

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  586 in total

1.  Gene expression profiling and association of circulating lactoferrin level with obesity-related phenotypes in Latino youth.

Authors:  J Y Kim; L E Campbell; G Q Shaibi; D K Coletta
Journal:  Pediatr Obes       Date:  2014-11-14       Impact factor: 4.000

2.  Intervention, integration and translation in obesity research: Genetic, developmental and metaorganismal approaches.

Authors:  Maureen A O'Malley; Karola Stotz
Journal:  Philos Ethics Humanit Med       Date:  2011-01-28       Impact factor: 2.464

3.  Reduction in inflammation and the expression of amyloid precursor protein and other proteins related to Alzheimer's disease following gastric bypass surgery.

Authors:  Husam Ghanim; Scott V Monte; Chang Ling Sia; Sanaa Abuaysheh; Kelly Green; Joseph A Caruana; Paresh Dandona
Journal:  J Clin Endocrinol Metab       Date:  2012-04-16       Impact factor: 5.958

4.  The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications.

Authors:  Chun Zeng; Xiaoyun Shi; Baojun Zhang; He Liu; Lianjun Zhang; Wenjun Ding; Yong Zhao
Journal:  J Mol Med (Berl)       Date:  2011-10-01       Impact factor: 4.599

Review 5.  Adipose tissue lymphocytes: types and roles.

Authors:  S Caspar-Bauguil; B Cousin; S Bour; L Casteilla; L Castiella; L Penicaud; C Carpéné
Journal:  J Physiol Biochem       Date:  2009-12       Impact factor: 4.158

6.  A regulatory subunit of phosphoinositide 3-kinase increases the nuclear accumulation of X-box-binding protein-1 to modulate the unfolded protein response.

Authors:  Jonathon N Winnay; Jeremie Boucher; Marcelo A Mori; Kohjiro Ueki; C Ronald Kahn
Journal:  Nat Med       Date:  2010-03-28       Impact factor: 53.440

7.  Serological evidence of infections and Type 2 diabetes: the MultiEthnic Study of Atherosclerosis.

Authors:  P L Lutsey; J S Pankow; A G Bertoni; M Szklo; A R Folsom
Journal:  Diabet Med       Date:  2009-02       Impact factor: 4.359

8.  Berson, Yalow, and the JCI: the agony and the ecstasy.

Authors:  C Ronald Kahn; Jesse Roth
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

Review 9.  Inflammation, insulin resistance, and obesity.

Authors:  Patrizia Ferroni; Stefani Basili; Angela Falco; Giovanni Davì
Journal:  Curr Atheroscler Rep       Date:  2004-11       Impact factor: 5.113

10.  Metabolic endotoxemia directly increases the proliferation of adipocyte precursors at the onset of metabolic diseases through a CD14-dependent mechanism.

Authors:  Elodie Luche; Béatrice Cousin; Lucile Garidou; Matteo Serino; Aurélie Waget; Corinne Barreau; Mireille André; Philippe Valet; Michael Courtney; Louis Casteilla; Rémy Burcelin
Journal:  Mol Metab       Date:  2013-07-04       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.